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Cornelia de Lange syndrome (CdLS) (Online Mendelian 
Inheritance in Man (OMIM) entries 122470, 300590, 
300882, 610759 and 614701) is a multisystem disorder 
with physical, cognitive and behavioural characteristics 
that is named after the Dutch paediatrician Cornelia de 
Lange, who first described the developmental disorder 
in two infants in 1933 (ref.1). The prevalence is estimated 
to be between 1 in 10,000 and 1 in 30,000 live births2.
Classic (or typical) CdLS is easily recognized from 
birth by experienced paediatricians and clinical geneti-
cists owing to a distinctive craniofacial appearance and 
growth pattern, as well as limb malformations (fig. 1). 
However, not all individuals with CdLS exhibit the clas-
sic phenotype, and presentation of the disorder can vary 
widely, from mild to severe and with different degrees of 
facial and limb involvement.
Over the past decade, genome- wide technolo-
gies, which can detect abnormal copy number and/or 
sequence variation, have emerged as a new first- line 
test for individuals with clinically significant develop-
mental disorders. While molecular investigations have 
successfully attributed the aetiology of CdLS to genetic 
variants of structural or regulatory components of the 
cohesin complex, using genotype as the gold standard 
for diagnosis has led to problems in clinical studies 
of CdLS. For example, plausibly causal variants have 
been identified in a confirmed CdLS gene, SMC1A, in 
individuals who exhibit no features of CdLS but have 
characteristics resembling rett syndrome3. As another 
example, plausibly causal variants were found in genes 
that had been associated previously with developmen-
tal disorders but not with CdLS, such as ANKRD11 and 
NAA10, in individuals with features of CdLS4,5. Finally, 
gene variants whose products are considered to func-
tion in the cohesin complex were reported in individuals 
who do not exhibit the classic CdLS phenotype. Taken 
together, this heterogeneity in presentation and causal 
genes has made it increasingly difficult to determine 
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Abstract | Cornelia de Lange syndrome (CdLS) is an archetypical genetic syndrome that is 
characterized by intellectual disability , well- defined facial features, upper limb anomalies and 
atypical growth, among numerous other signs and symptoms. It is caused by variants in any one  
of seven genes, all of which have a structural or regulatory function in the cohesin complex. 
Although recent advances in next- generation sequencing have improved molecular diagnostics, 
marked heterogeneity exists in clinical and molecular diagnostic approaches and care practices 
worldwide. Here, we outline a series of recommendations that document the consensus of a 
group of international experts on clinical diagnostic criteria, both for classic CdLS and non-classic 
CdLS phenotypes, molecular investigations, long- term management and care planning.
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Phenotype
All morphological and 
functional attributes of an 
individual or of the organs, 
tissues or cells of that 
individual, except for the 
primary morphology of the 
genome.
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which combination of characteristics should still be 
called CdLS6.
The overall CdLS phenotype can be characterized 
as a spectrum (fig. 2) to which the classic CdLS phe-
notype belongs as well as syndromes with a similar but 
non- classic phenotype caused by pathogenic variants 
in genes involved in cohesin functioning. A group of 
entities also caused by pathogenic variants in genes 
involved in cohesin functioning but showing only very 
limited overlap with the classic CdLS phenotype, such 
as Roberts syndrome (OMIM 268300) and Nicolaides–
Baraitser syndrome (OMIM 601358), are not considered 
to be part of the CdLS spectrum. To date, there is no 
individual with a classic CdLS phenotype known to us in 
whom a variant in a gene without cohesin function has 
been reliably shown to be causative. All known causes of 
CdLS can thus be categorized as cohesinopathies, but not 
all cohesinopathies result in CdLS.
From the patient and family perspective, grouping 
individuals with a specific disorder facilitates knowledge 
exchange, establishes contact between affected individ-
uals and their families who can support each other, and 
increases attention from scientists. However, indicating 
differences is also useful to tailor care to the individual. 
Recognizing the great phenotypic variability of CdLS and 
the wide heterogeneity in diagnostics, care and manage-
ment of individuals with CdLS, a group of international 
experts, representing the Scientific Advisory Council 
of the World Federation of CdLS Support Groups, 
established an International CdLS Consensus Group to 
address these issues and define a series of recommenda-
tions that are presented in this Consensus Statement (for 
recommendations R1–R68, see Supplementary Box 1).
Methods
The International CdLS Consensus Group comprised 
43 participants from 30 institutions in 9 countries. 
The group consisted of clinicians, scientists and two 
patient- group representatives. The clinicians practice 
in North America, South America and Europe. A mod-
ified Delphi consensus process was adopted (TAble 1). 
Discussions occurred via video conference calls, e- mail 
communications and file exchanges. All known support 
groups were contacted by e- mail to identify key issues 
that should be addressed during the consensus process. 
Subsequently, the issues to be addressed were deter-
mined by the Consensus Group in a video conference 
call. A plenary face- to-face 2-day meeting of 17 partici-
pants (including the patient- group representatives) was 
held in November 2017. Consensus recommendations 
were voted on by 37 participants (for recommendations 
R1–R68, see Supplementary Box 1).
Clinical diagnostic criteria
Clinical features
A combination of signs and symptoms defines the classic 
CdLS phenotype. We have classified these into cardinal 
features, considered to be the most characteristic for 
CdLS, and suggestive features, which add to the diagno-
sis but are less specific (box 1; fig. 3) (R1). We developed 
consensus criteria using these features: a score of ≥11 
indicates classic CdLS if at least three cardinal features are 
present; a score of 9–10 indicates non- classic CdLS if at 
least two cardinal features are present; a score of ≥4 is suf-
ficient to warrant molecular testing for CdLS if at least one 
cardinal feature is present; a score below <4 is insufficient 
to indicate such testing (R2). A score of ≥11 confirms the 
diagnosis of CdLS regardless of whether a pathogenic 
variant in one of the known genes can be found.
We tested the clinical diagnostic criteria in a series of 
75 individuals with an NIPBL variant, 62 of whom had 
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been scored in the past — independently of the present 
criteria — as having the classic phenotype, and 13 of 
whom were reported to have a non- classic pheno type2,3. 
Individuals with a classic phenotype and an NIPBL vari-
ant had a score between 12 and 16 (mean 13.5; cardinal 
features 3–5, mean 3.9), and those with the non- classic 
CdLS phenotype had a score between 9 and 11 (mean 
10.0; cardinal features 2–3, mean 3.0). We also tested 46 
individuals with an SMC1A variant, of whom 40 were 
identified as having a CdLS phenotype, and 6 were deter-
mined to have a phenotype resembling Rett syndrome3. 
Individuals with an SMC1A variant and a CdLS pheno-
type had a score between 2 and 13 (mean 8.0; cardinal 
features mean 2.9), and those with a Rett- like phenotype 
had a mean score of 3.5 (2–5; cardinal features mean 0.7). 
No individual with a CdLS phenotype and a molecular 
confirmation of a variant in NIPBL and SMC1A would 
have been missed using the presently proposed crite-
ria. We tested the specificity of the clinical diagnostic 
criteria by applying them to a series of individuals with 
any of three entities that resemble CdLS (Coffin–Siris 
syndrome7, Rubinstein–Taybi syndrome8 or Nicolaides–
Baraitser syndrome9); no individual scored as having a 
classic CdLS phenotype, and 4–10% scored as having a 
non- classic phenotype, indicating excellent discrimina-
tory ability. The true specificity can be determined only 
in a separate, dedicated study.
Severity scores
Several scoring procedures have been described to 
indicate the severity of CdLS2,10–12. No score takes the 
severity as experienced by the families into account, nor 
estimates the severity of all organ systems that may be 
affected in CdLS. We suggest that existing severity scores 
should be used with caution and acknowledge the need 
for the development of a severity score that represents 
severity as experienced by families, preferably stratified 
by genetic cause (R3).
Molecular diagnostic criteria
Genetics of CdLS
The CdLS spectrum has been associated with molecular 
abnormalities affecting genes involved in chromatin regu-
lation, most commonly those involving the cohesin com-
plex13–18 (fig. 4). Cohesin is an essential regulator of most 
aspects of chromosome biology, including chromo some 
segregation, maintenance of genome stability, regulation 
of gene expression, chromatin structure and genome 
organization19–22. Although the exact pathomechanisms 
in CdLS are currently not fully understood, the direct role 
of cohesin as a regulator of gene expression is estimated 
to be of crucial importance for cohesin function.
In 2004, Nipped- B-like protein (NIPBL) was identi-
fied as the human homologue of the fungal and fly sister 
chromatid cohesion protein 2 (SCC2), which together 
with SCC4 forms a complex that is necessary for cohesin 
loading onto chromosomes, and variants in NIPBL were 
identified as the cause of classic CdLS13,14. Since then, 
cohorts of individuals with classic, non- classic and over-
lapping phenotypes have been screened for gene variants 
of other cohesin core and regulatory proteins, leading to 
the detection of variants in six additional genes causal 
of CdLS: SMC1A, SMC3, RAD21, BRD4, HDAC8 and 
ANKRD11 (R4). In a study in which 44 individuals were 
studied for all 5 genes known at the time to cause CdLS 
(NIPBL, SMC1A, SMC3, RAD21 and HDAC8), and 
including a search for mosaicism, a causative variant was 
detected in 84% of individuals23. The clinical features of 
individuals with variants in the seven known genes differ 
in several aspects (TAble 2).
NIPBL. Variants in NIPBL can be identified in approx-
imately 70% of cases. Multiple studies have noted that 
loss- of-function variants cause more severe clinical 
features than missense variants, which are typically, 
albeit not always, associated with a less marked pheno-
type10,11,24–26. In addition to single nucleotide variants, 
microdeletions or intragenic exon deletions have been 
identified in 3% of cases10,27,28. Furthermore, a substantial 
number of individuals with classic CdLS carries mosaic 
NIBPL variants23. While individuals with the classic 
CdLS phenotype are likely to have variants in NIPBL, 
individuals with variants in one of the other causative 
CdLS genes can also fulfil the criteria for classic CdLS.
SMC1A. SMC1A encodes structural maintenance of 
chromosomes protein 1A, a core component of the 
cohesin complex (fig. 4), and variants in this gene have 
been identified in an estimated 5% of individuals with 
CdLS3. Many individuals usually display a non- classic 
phenotype3,15,16,24,29 and have fuller eyebrows, a less strik-
ing shortening of the nasal bridge and a rounder face 
than individuals with NIPBL variants. A subset (40%) 
of individuals with SMC1A variants (as ascertained by 
panel sequencing for genes involved in intellectual dis-
ability) present with a phenotype distinct from CdLS 
a b c d
e f g h
Fig. 1 | Facial phenotype of individuals with Cornelia de Lange syndrome.  
a | Classic Cornelia de Lange syndrome (CdLS) phenotype resulting from an NIPBL 
variant. b | Non- classic CdLS phenotype in an individual harbouring an NIPBL variant. 
c | Adult with the classic phenotype (NIPBL variant). d | Non- classic phenotype in 
individual with an SMC1A variant. e | Classic phenotype in an individual with an SMC3 
variant. f | Non- classic phenotype in an individual with a RAD21 variant. g | Non-classic 
phenotype in an individual with an HDAC8 variant. h | Non- classic phenotype in an 
individual with an ANKRD11 variant.
Cohesin complex
A multisubunit protein complex 
that mediates sister chromatid 
cohesion and cellular 
long-distance chromatin 
interactions. in vertebrates, the 
cohesin complex is composed 
of structural maintenance of 
chromosomes protein 1A 
(SMC1A), SMC3, rAD21  
and cohesin subunit SA1  
(also known as STAg1).
Genotype
The primary DNA sequence, 
either overall or at a specific 
locus, of an individual or of the 
organs, tissues or cells of that 
individual.
Rett syndrome
A severe, progressive 
neurological disorder primarily 
affecting females that is mainly 
caused by mutations in the 
gene encoding 
methyl-Cpg-binding protein 2 
(MeCP2). it is characterized by 
loss of acquired speech and 
motor skills, repetitive hand 
movements, breathing 
irregularities and seizures.
Cohesinopathies
Disturbances of the function of 
the cohesin complex that lead 
to altered human 
development.
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that often resembles Rett syndrome3,30,31. SMC1A is an 
X- linked gene that is not inactivated32, and in the few 
families reported to date, female individuals are less 
affected than male individuals3,15. One parent, who 
showed no symptoms or signs of CdLS, was reported to 
harbour a mosaic SMC1A variant16.
SMC3. In 2007, a series of 115 individuals with CdLS 
was specifically investigated for variants in SMC3, which 
encodes another component of the cohesin complex 
(fig. 4), and a single individual with atypical CdLS was 
found to have a variant in this gene16. SMC3 variants are 
uncommon causes of CdLS33 and were also identified 
in individuals with intellectual disability, short stature 
and congenital anomalies who do not fulfil the clinical 
diagnostic criteria of non- classic CdLS24,33. SMC3 var-
iants identified in individuals with CdLS are typically 
missense changes33, suggesting that loss- of-function 
variants are not tolerated.
RAD21. Double- strand break repair protein rad21 
homologue (RAD21) is another protein that is part of the 
cohesin complex34. To date, 13 individuals with RAD21 
variants have been reported, and our mutual experience 
adds 10 further variants, suggesting that RAD21 variants 
comprise a small percentage of causes for CdLS. The first 
RAD21 variants were reported in two individuals with a 
non- classic CdLS phenotype17. The subsequently reported 
individuals with a RAD21 variant also had a non- classic 
phenotype24,35. Truncating and missense RAD21 variants 
and intragenic deletions have been noted36, and missense 
variants were also reported in individuals without CdLS 
features4,36. The limited number of reported individuals 
precludes any genotype–phenotype correlation.
BRD4. Bromodomain- containing protein 4 (BRD4) is 
a chromatin- associated protein that localizes to clusters 
of enhancers by binding to acetylated histone H3 Lys27 
(H3K27ac)37. The encoding gene was first implicated in 
CdLS when a de novo deletion that included BRD4 was 
identified in an individual with an atypical CdLS pheno-
type; targeted sequencing subsequently determined 
de novo intragenic variants in BRD4 (ref.18). Mass spec-
trometry identified NIPBL as a prevalent interacting 
protein in BRD4 immunoprecipitates, and missense 
variants were found to ablate the interaction with the 
acetylated histone while retaining the NIPBL associa-
tion18, suggesting that sequestration of NIPBL underlies 
the pathogenic mechanism. The number of individuals 
with BRD4 variants is too small to draw conclusions 
regarding the most common phenotype.
HDAC8. The first variants in HDAC8 were reported in 
individuals with classic CdLS and in those with non- 
classic CdLS38 and in a family with X- linked intellectual 
disability and a phenotype that did not resemble CdLS39. 
To date, 65 individuals with HDAC8 variants have been 
reported24,38–42. The variation in phenotype is remarkably 
wide and is typically non- classic, but some individuals 
fulfil the criteria for classic CdLS (box 1). Distinctive fea-
tures in affected individuals in addition to those of CdLS 
include a large anterior fontanel, widely spaced eyes (also 
known as orbital hypertelorism) and happy personali-
ties. HDAC8 is located on the X chromosome and can 
be inactivated41. Female carriers can be either affected 
or completely healthy, presumably depending on which 
X chromosome is inactivated. Most female individuals 
who are heterozygous for pathogenic HDAC8 variants 
demonstrate marked skewing of X- inactivation towards 
the wild- type allele41,42.
ANKRD11. To date, five de novo ANKRD11 variants 
have been reported in individuals with a non- classic 
CdLS phenotype24,43, and additional variants have been 
identified in clinical and research cohorts (unpub-
lished observations, A.D.K., D.F., F.J.K. and R.C.H.). 
These patients have features that overlap with CdLS in 
facial gestalt, as well as some minor CdLS features (box 1).
Other genes. In the search for further causes of CdLS, 
variants in several additional genes have been identi-
fied by exome sequencing; however, these variants were 
detected in individuals exhibiting limited clinical CdLS 
features rather than in individuals fulfilling the clinical 
diagnostic criteria for CdLS. De novo variants in EP300 
were detected in individuals with some features sugges-
tive of CdLS44, and de novo AFF4 variants have been 
reported in three individuals with CHOPS syndrome, 
CdLS spectrum
Variant in a gene involved in
dysregulated cohesin functioning
Variant in
other gene ?
Non-classic CdLS
phenotype
Other phenotypes sharing
limited signs of CdLS
Classic CdLS
phenotype
Fig. 2 | The phenotypes classified as Cornelia de Lange syndrome can be defined as 
a spectrum. The Cornelia de Lange syndrome (CdLS) spectrum includes individuals with 
the classic CdLS phenotype in whom a pathogenic variant in a gene involved in cohesin 
functioning has or has not been identified (if molecular confirmation is absent, the 
diagnosis can still be determined clinically), as well as individuals with a non- classic CdLS 
phenotype who harbour a pathogenic variant in a cohesin function- relevant gene. 
Individuals who carry a presumed pathogenic variant in a cohesin function- relevant gene 
but exhibit little or no resemblance to the classic CdLS phenotype do not fall within the 
CdLS spectrum. Please note that mildly affected and severely affected individuals may 
present both classic and non- classic CdLS. The question mark indicates that there may 
be genes causing CdLS spectrum that do not have a cohesin function; such genes are 
unknown at present, but their existence cannot be excluded.
Table 1 | Details of the Delphi consensus voting process
Level of 
evidence
Definition Votes (%)
+++ Evidence or general agreement indicate full agreement 
with the recommendation
≥70
++ Evidence or general agreement favour the 
recommendation
50–69
+ Evidence or general agreement are weak for the 
recommendation
26–49
– Insufficient evidence or general agreement for the 
recommendation
<26
Voting was performed digitally by 37 co- authors of the guidelines. For all recommendations, >90% 
was in full agreement with the recommendations. Patient group representatives did not vote.
Delphi consensus process
A structured communication 
process between a panel of 
experts.
Mosaicism
The presence of two or more 
populations of cells with 
different genotypes in a single 
individual, who has developed 
from a single fertilized egg cell.
Facial gestalt
The unified pattern of elements 
of facial characteristics that 
cannot be derived from the 
simple summation of its 
elements.
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which stands for cognitive impairment, coarse facies, 
heart defects, obesity, pulmonary involvement, short 
stature and skeletal dysplasia and includes features that 
overlap with CdLS45. Variants in NAA10 have been 
described in a series of individuals with some resem-
blance to individuals with CdLS that is limited to the 
periorbital region5. Finally, recessive TAF6 variants have 
been reported in two families with children who showed 
features that overlap with CdLS4.
Mosaicism
Mosaicism has been found to occur frequently in 
CdLS23. Approximately 15–20% of individuals with clas-
sic features have mosaic NIPBL variants that cannot be 
detected in lymphocytes23,24,46. Rarely, individuals with 
CdLS can harbour mosaic SMC3 (ref.24), RAD21 (ref.24) 
or SMC1A variants (unpublished observations, D.F. and 
F.J.K.). It is assumed that mosaicism leads to variation in 
severity of the clinical phenotype but there is no formal 
proof of this at present. Selection against haematopoietic 
cells expressing variant HDAC8 has been reported41, and 
the absence of NIPBL variants in blood cells but their 
presence in other tissues23,46 suggests that haematopoietic 
selection for expression of the normal allele occurs with 
NIPBL mosaicism. The gold standard for the identifi-
cation of mosaicism is evaluation of DNA from uncul-
tured fibroblasts, but circumstances may dictate the 
use of other tissues (R5). Analysis of DNA from buccal 
cell swabs, cultured fibroblasts, bladder epithelial cells, 
uncultured skin biopsy samples or surgical specimens 
has improved the detection rate for mosaic variants23,24.
Familial recurrence risk
No large studies have been performed to deter-
mine gene- based familial recurrence risks in CdLS. 
Infrequently, families in which non- classic CdLS seg-
regates in an autosomal dominant manner have been 
reported, as has germline mosaicism leading to affected 
siblings born to unaffected parents47,48. Our joint expe-
rience in 560 families including an individual with a 
causal NIPBL variant suggests that the familial recur-
rence risk owing to gonadal mosaicism is 0.89% (unpub-
lished observations, A.D.K., M.A.D., F.J.R., J.W., V.C.-D., 
D.F., F.J.K., J.P., E.R. and R.C.H.). The recurrence risks 
for the X- linked SMC1A and HDAC8 variants follow 
general rules of X- linked inheritance; by far, most have 
occurred as de novo events. If no molecular evaluation 
can be performed, the empirical recurrence risk is 1.5%49 
(R6). Genetic counselling may be especially difficult for 
families in whom variants have been detected in SMC1A, 
HDAC8 and RAD21 owing to the remarkable variability 
of the phenotype, even within families3,35,41,42.
Diagnostic approaches
Prenatal diagnostics. The major indications for pre-
natal diagnostics are an earlier child with CdLS, a new 
pregnancy in a family with a known genetic alteration 
in a CdLS gene or, as occurs most frequently, no family 
history but features suggestive of CdLS on fetal ultra-
sonography. In 73 published cases involving patients 
with prenatal findings suggestive of CdLS, symmetric 
intrauterine growth restriction (IUGR) with onset in 
the second trimester was noted as the most common 
finding (80%)50. Limb anomalies were seen in 66% of 
fetuses (likely representing a selection bias), and approx-
imately 50% of fetuses had an abnormal facial profile 
(micrognathia and prominent maxilla)51. Other reported 
findings include increased nuchal thickness (51%), dia-
phragmatic hernia (28%) and cardiac malformation 
(15%)50. When considering prenatal investigations, the 
pros and cons of the prenatal studies need to be dis-
cussed with the parents to offer investigations tailored 
to their wishes and to the technical, medical and legal 
options available (R7).
Prenatal molecular testing can be performed on sam-
ples obtained from chorionic villous sampling or amnio-
centesis or by testing embryonic cells obtained through 
in vitro fertilization. Single- gene sequencing with or 
without deletion or duplication testing is used most fre-
quently, but the advent of panel testing of chorionic villi 
or amniocytes allows assessment of all known causative 
genes in a single test in some countries (R8).
Non- invasive cell- free fetal DNA multi- gene screening 
that includes CdLS genes can identify de novo variants 
in families without a previous child who has CdLS. 
However, comparison with both biological parental sam-
ples is essential to interpret the large number of variants 
for which pathogenicity may be difficult or impossible 
to determine, which precludes meaningful use of this 
approach in routine practice at the present. Owing to the 
complexity of the molecular findings, prenatal testing 
for CdLS outside of a known familial pathogenic var-
iant remains challenging. Interpretation of novel vari-
ants requires caution as pathogenicity may be difficult to 
Box 1 | Clinical features of Cornelia de Lange syndrome
Cardinal features (2 points each if present)
•	Synophrys (HP:0000664) and/or thick eyebrows (HP:0000574)
•	Short nose (HP:0003196), concave nasal ridge (HP:0011120) and/or upturned nasal tip 
(HP:0000463)
•	long (HP:0000343) and/or smooth philtrum (HP:0000319)
•	Thin upper lip vermilion (HP:0000219) and/or downturned corners of mouth 
(HP:0002714)
•	Hand oligodactyly (HP:0001180) and/or adactyly (HP:0009776)
•	Congenital diaphragmatic hernia (HP:0000776)
Suggestive features (1 point each if present)
•	Global developmental delay (HP:0001263) and/or intellectual disability (HP:0001249)
•	Prenatal growth retardation (<2 SD) (HP:0001511)
•	Postnatal growth retardation (<2 SD) (HP:0008897)
•	microcephaly (prenatally and/or postnatally) (HP:0000252)
•	Small hands (HP:0200055) and/or feet (HP:0001773)
•	Short fifth finger (HP:0009237)
•	Hirsutism (HP:0001007)
Clinical score
•	≥11 points, of which at least 3 are cardinal: classic CdlS
•	9 or 10 points, of which at least 2 are cardinal: non- classic CdlS
•	4–8 points, of which at least 1 is cardinal: molecular testing for CdlS indicated
•	<4 points: insufficient to indicate molecular testing for CdlS
Definitions according to elements of morphology. Human phenotype ontology identifier 
(HPo ID) numbers listed between brackets. CdlS, Cornelia de lange syndrome.
Cell-free fetal DNA
Circulating DNA in maternal 
plasma originating from the 
fetus.
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determine, and the possibility of undetectable mosaicism 
often precludes using testing for exclusion purposes. For 
these reasons, the validity and informative value of pre-
natal test results, and the ethical issues these may raise 
for families in deciding whether to continue a preg-
nancy, must be considered and discussed with couples 
before sampling.
Molecular genetic testing. Panel sequencing is the most 
effective way of detecting causative variants in any of 
the genes known to cause CdLS, and first- line molecu-
lar testing should use a panel that contains at least 
the seven known CdLS genes (fig. 5). Most diagnostic 
laboratories include several additional genes that can 
cause a phenotype resembling CdLS, such as CREBBP  
and EP300.
We realize that the availability of panel sequencing 
varies widely around the world, and financial constraints 
may dictate that clinicians work with other technologies. 
If panel sequencing is unavailable, Sanger sequencing 
of NIPBL in an individual with the classic phenotype 
would be the preferred approach for molecular testing. 
For individuals with non- classic phenotypes, evaluation 
of the phenotype may allow experienced clinicians to 
determine which of the other candidate genes should 
be sequenced first (R9).
If panel or Sanger sequencing does not detect 
causal variants, a study aimed at detecting mosai-
cism should be considered, preferably using uncul-
tured fibroblasts, although buccal cells or bladder 
epithelial cells can also be used. If negative, test-
ing for deletions or duplications of NIPBL using 
multiplex ligation- dependent probe amplification (MLPA) 
should be considered.
Medical follow- up
Paediatric medical follow- up
Given that CdLS can usually be recognized from birth, 
the paediatrician has a central role in clinical care. 
Once the clinical diagnosis of CdLS has been confirmed, 
every infant or child needs to be evaluated for common 
associated major malformations that require manage-
ment or surveillance. Routine echocardiography and 
renal sonography are indicated in every diagnosed infant 
and child, given that 25% of individuals with CdLS have 
a cardiac anomaly and 10% have a renal malformation49. 
In adolescents, the usefulness of such studies should be 
guided by symptomatology (R10). Central nervous sys-
tem imaging is indicated only if neurological symptoms 
such as seizures present, which is rare. Treatment and 
surveillance of major malformations are the same as for 
children without CdLS. In 50% of children with CdLS 
who have undergone intubation, the procedure has been 
difficult. Moreover, an adverse allergic reaction to mida-
zolam (a short- acting benzodiazepine used for sedation) 
can occur52, although complications due to anaesthetic 
medications are rare53.
CdLS- specific growth charts are available54. Weight 
at birth is usually below the 5th percentile, and height, 
weight and head circumference all remain below the 
ranges for the general population (R11). The growth 
charts are derived from clinically diagnosed individ-
uals, and no growth charts subdivided by molecular 
background are available. Growth is influenced by the 
nature of the variant and the causative gene10,24 and tends 
to be less compromised in individuals with SMC1A 
variants compared with those with NIPBL variants3. 
If growth velocity is lower than expected, gastrointestinal 
problems, thyroid dysfunction and growth hormone dis-
turbances should be considered. Growth hor mone secre-
tion is normal in most children55, although a single child 
with a NIPBL variant with low growth hormone levels 
and an increase in growth after supplementation has 
been described56. The benefits of increased growth by 
growth hormone supplementation should be weighed 
against the burden of daily subcutaneous injections and 
the lack of a positive impact of an increased adult height 
on the quality of life for most individuals with CdLS.
Feeding difficulties are almost universally present 
in neonates and infants with CdLS and often in chil-
dren and adults as well. Oral feeding is preferred if it is 
safe and stress- free and if feeding time does not exceed 
3 hours per day, otherwise enteral feeding is recom-
mended57. Involvement of dieticians is essential (R12, 
R13). Gastrostomies are the preferred option if tube feed-
ing is needed for a prolonged period of time. Cleft palate, 
micrognathia and dental issues may contribute to feed-
ing difficulties57. Cleft palate, including submucous cleft 
palate, occurs in 20% of individuals with CdLS. Isolated 
cleft lip is not related to CdLS. Dental problems consist of 
delayed secondary tooth eruption, small or absent teeth, 
malposition, malocclusion, overcrowding of teeth, dental 
caries on the perilingual maxillary surface (due to gastro- 
oesophageal reflux disease (GERD)), periodontal disease 
and bruxism. Dental problems are worsened by poor 
oral hygiene, especially in those with marked intellec-
tual disability, and owing to limited patient compliance58  
Synophrys
Thick eyebrows
Short nose
Thin upper lip
vermilion
Concave nasal ridge
Upturned nasal tip
Long, indistinct philtrum
Downturned corners
of mouth
Fig. 3 | Cardinal facial features of Cornelia de Lange syndrome. Facial features 
that are the most characteristic for Cornelia de Lange syndrome (CdLS) include eye 
manifestations such as synophrys (meeting of the medial eyebrows in the midline) 
and thick eyebrows, a short nose, concave nasal ridge and upturned nasal tip,  
a long and smooth philtrum, a thin upper lip vermilion and downturned corners  
of the mouth. Non- facial features (not shown) that are considered to be cardinal 
features of CdLS include hand oligodactyly (the congenital absence of one or more 
fingers), adactyly (the absence of all fingers and/or toes) and congenital 
diaphragmatic hernia.
Multiplex ligation-dependent 
probe amplification
(MlPA). A molecular technique 
involving the ligation of two 
adjacent annealing 
oligonucleotides followed by 
quantitative PCr amplification 
of the ligated products, 
allowing the characterization of 
chromosomal aberrations in 
copy number or sequence and 
single nucleotide 
polymorphism or mutation 
detection.
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(R14, R15), which may lead to early- onset dental decay 
and periodontal disease59. Dental treatment by an inter-
disciplinary health- care team, a healthy diet, topical 
fluoride application and periodic dental check- ups are 
crucial in optimal management60,61.
Motor development is invariably delayed. Reliable 
data for a large series of individuals with molecularly 
confirmed diagnoses are not available. In a small series 
(n = 51), children with SMC1A variants reached several 
milestones (sitting, walking and first words) at a younger 
age than children with NIPBL variants3. In the latter 
group, at 5 years of age, 99% were able to sit, 63% could 
walk independently and 38% had started to speak (R16).
Vaccinations should be given according to national 
schemes (R17). Recurrent respiratory infections are 
common and are thought to be secondary to altered 
anatomy, hypotonia and coordination of swallowing and 
coughing. Immunological anomalies occur occasion-
ally; if unusually frequent or severe infections are pres-
ent, further studies are indicated62. Thrombocytopenia 
has been reported but is usually non- progressive and 
asymptomatic63,64, and specific testing is not needed.
Pain can occur in children with CdLS, especially 
owing to dental problems, bladder and upper res-
piratory tract (including ears and sinuses) infections, 
gastro- oesophageal reflux and/or hip anomalies. Limited 
communicative abilities may hamper the shared recog-
nition of pain65, and pain can lead to substantial behav-
ioural problems. If there is suspicion that a patient with 
CdLS is in pain, the use of specific tools to identify pain 
in an individual with intellectual disability, such as the 
face, legs, activity, cry, consolability (FLACC) assessment 
tool, is recommended66 (R18).
Most individuals with CdLS will go through puberty. 
In clinically diagnosed individuals, puberty was mildly 
delayed (mean age of onset was 15 years for boys and 
13 years for girls)2. That is, on average, menarche is 
delayed by 1 year compared with the general population; 
5% of girls with CdLS will never menstruate. For those 
who do, the menstrual cycle often remains irregular. 
A bicornuate uterus is found in 19% of female patients, 
and approximately 80% of girls develop breast tissue. 
In boys with CdLS, 80% exhibit cryptorchidism, 37% 
have a small penis and 9% have hypospadias2. Surgical 
correction of cryptorchidism is recommended to reduce 
the risk of testicular cancer, as in the general popula-
tion. No lowering of voice in boys at puberty has been 
reported2. Teenagers with CdLS can become overweight 
or develop overt obesity, which is often induced by high- 
calorie food offered by caregivers in combination with 
limited physical activity2; regular evaluation of weight 
is essential.
Preferably, all individuals with CdLS should be 
followed up by a paediatrician experienced in CdLS. 
Follow- up varies between countries but is frequent in 
infancy and early childhood, and annually to once every 
3–5 years in adolescence and adulthood. In case of prob-
lems, the schedule should be adapted to include more 
frequent follow- up visits (R19).
Adult medical follow- up
Currently, most people with CdLS reach adulthood 
owing to improved care, especially in the first year of 
life. Individuals with CdLS aged ≥50 years have been 
described23,67. Care coordination in adults is required, 
as many medical disciplines are typically involved.
RNAPII
ANKRD11
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RAD21
Fig. 4 | Cornelia de Lange syndrome is a cohesinopathy. Cornelia de Lange syndrome (CdLS) is caused by genetic 
variants that affect subunits or regulators of the cohesin complex. The structural core components double- strand break 
repair protein rad21 homologue (RAD21), structural maintenance of chromosomes protein 1A (SMC1A) and SMC3 of 
cohesin are thought to form a tripartite ring entrapping chromatids. In humans, cohesin subunit SA1 (STAG1), STAG2 or 
STAG3 directly attach to the ring and form part of the core complex. Nipped- B-like protein (NIPBL) and MAU2 chromatid 
cohesion factor homologue form a heterodimeric complex named kollerin that is required for cohesin loading onto DNA , 
and in which bromodomain- containing protein 4 (BRD4) interacts with NIPBL. Histone deacetylase 8 (HDAC8) regulates 
the cohesin complex release from chromatin by deacetylating SMC3. The functional interaction of ankyrin repeat domain- 
containing protein 11 (ANKRD11) with cohesin is under study but is currently unknown. Ac, acetyl group; AFF4, AF4/FMR2 
family member 4; EF, elongation factor ; RNAPII, RNA polymerase II; TF, transcription factor.
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A small number of women with CdLS have given 
birth, and often the diagnosis in the mother has been 
made only after diagnosis of the child3,36,41,68. A few men 
with CdLS are known to have fathered a child69,70, but 
reliable data on male fertility are not available. Sexual 
education should be offered appropriate to the level 
of socioemotional and cognitive functioning71 (R20). 
Contraceptive options are the same as for the general 
population. For some individuals, suppression of menses 
is preferred, and several contraceptives can effectively 
control or suppress menstruation. Hysterectomy is not 
recommended as a primary method of contraception but 
is sometimes employed for menorrhagia that does not 
respond to treatment72 (R21). Premenstrual syndrome 
and dysmenorrhoea occur in women with CdLS and 
can be associated with behavioural changes. Treatment 
options are as in the general population. We found no 
mention of menopause in CdLS in the literature, and 
no reliable studies on osteoporosis are available.
Several studies49,59 indicate that >30% of adults with 
CdLS are overweight, and at least 50% are considered 
obese. It remains uncertain whether this percentage is 
higher than in individuals with the same cognitive level 
and mobility. Obviously, caution with diet and physical 
Table 2 | Comparison of the main clinical findings in individuals with molecularly confirmed Cornelia de Lange syndrome
HPO ID* NIPBL SMC1A SMC3 BRD4 HDAC8 RAD21 ANKRD11
Growth
IUGR 0001511 +++ ++ + ++ ++ ++ −
Short stature 0004322 +++ ++ ++ + + ++ ++
Microcephaly 0000252 ++++ ++ ++ ++ + ++ +
Craniofacial features
Brachycephaly 0000248 ++ + +++ + +++ ++ +
Low anterior hairline 0000294 +++ +++ +++ ++ ++ + +
Arched, thick eyebrows 0002253, 0000574 +++ +++ ++++ +++ +++ +++ +
Synophrys 0000664 ++++ +++ +++ +++ ++++ +++ +
Long eyelashes 0000527 ++++ +++ +++ + + +++ +
Depressed nasal bridge 0005280 +++ + + + + + −a
Anteverted nostrils 0000463 +++ ++ ++ ++ +++ +++ +
Broad nasal tip 0000455 ++ ++ +++ + + − ++
Long, smooth philtrum 0000343, 0000319 +++ ++ ++ ++ ++ ++ ++
Thin upper vermilion 0000219 ++++ +++ +++ ++ + +++ ++
Downturned corners of the mouth 0002714 ++++ +++ ++ + ++ +++ −
Highly arched palate 0000218 ++ + + + + ++ +
Widely spaced teeth 0000687 +++ + + − ++ − −b
Micrognathia 0000347 +++ + + ++ ++ + −
Low- set and malformed ears 0000369, 0000377 ++ + + − + + −
Trunk and limbs
Oligodactyly and adactyly (hands) 0012165, 0009776 + − − − − − −
Small hands 0200055 +++ +++ +++ ++ ++++ +++ ++
Proximally placed thumbs 0009623 ++ + +++ +++ +++ + −
Clinodactyly or short fifth finger 0004209, 0009237 +++ + ++ + ++ +++ ++
Small feet 0001773 ++++ ++ +++ NR +++ +++ +
Hirsutism 0001007 +++ +++ ++++ − + ++ ++
Cardiovascular anomalies 0002564 + + + + + + −
Vertebral anomalies 0003468 − − + − − ++ +++
Cognition and behaviour
Intellectual disability (any degree) 0001249 ++++ ++++ ++++ ++++ ++++ + ++++
ASD 0000729 + + + − + + +
Self- injurious behaviour 0100716 +++ + NR + + − ++
Stereotypic movements 0000733 ++ ++ NR NR − − −
ASD, autism spectrum disorder ; HPO ID, Human Phenotype Ontology identifier ; IUGR , intrauterine growth retardation; NR , not reported. ++++, ≥90%; +++, 70–89%; 
++, 50–69%; +, 20–49%; −, <20%. aProminent nasal bridge. bMacrodontia (larger than normal teeth).
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activity is indicated (R22). Type 2 diabetes mellitus 
develops in 4% of individuals2.
Organ involvement is similar to that seen in the paedi-
atric population and is discussed according to the major 
affected systems in detail below. Congenital heart 
anomalies should be detected in infancy or childhood 
and typically do not cause unexpected complications in 
adulthood. Hypertension and congestive heart failure 
have been reported in 4–8% and 2–4% of individuals 
with CdLS, respectively2,73. Fatal coronary occlusion and 
pulmonary artery embolism have been reported once67. 
In a retrospective cohort of 97 adults, 2 individuals had a 
myocardial infarction, and 2 had strokes73. Renal failure 
was reported in 1% of individuals but is rarely fatal73. 
Structural renal malformations were reported in 30% of 
adults; of these, 24% had abnormal creatinine clearance 
rates. It is recommended that renal function be mon-
itored in those with structural renal malformations64 
(R23). Prostate enlargement has been found in 10% of 
men by the age of 41 years, requiring prostate removal 
in one individual74. In the general population, benign 
prostatic hypertrophy is found in 25% of men in their 
fifties75, and international management recommenda-
tions, which can be followed for men with CdLS as well, 
start at age 45 years76 (R24).
Cancer of the oesophagus has been reported in 
three individuals with Barrett oesophagus. There is no 
increased risk of cancer at a young age, but reliable data 
for middle- aged and older individuals are not avail-
able. Screening for cervical and breast cancer should be 
performed according to standard guidelines77,78 (R25, R26).
In a study of 295 individuals with CdLS (81 infants, 
117 children and 97 adults; 15 with a confirmed NIPBL 
variant), the most common causes of death in infants 
were congenital diaphragmatic hernia (17%) and res-
piratory problems (13%); in children, mortality was 
greatest owing to sequelae of congenital heart defects 
(10%) and respiratory (32%) and gastrointestinal prob-
lems (18%)73. No reliable data are available for the risk 
of death in infancy or childhood. Causes of death in 
adults are related to the gastrointestinal, pulmonary and 
cardiac systems, as well as to infections or to anaesthe-
sia2,67,73,79. In several countries, individualized medical 
alert cards (also known as emergency cards) that report 
the main clinical data of the patient and the most fre-
quent and potentially life- threatening medical compli-
cations of CdLS are used to the satisfaction of families 
and caregivers alike (Supplementary Boxes 2,3) (R27).
Organ system manifestations
Gastroenterology
Individuals with CdLS have more frequent gastrointes-
tinal malformations, such as duodenal atresia, annular 
pancreas80, imperforate anus81, Meckel diverticulum59 
and congenital diaphragmatic hernia82,83. Pyloric ste-
nosis has been reported in up to 7% of patients2,35, and 
inguinal hernia is common in childhood2 (R28).
Intestinal malrotation has been reported in 5% of a 
series of 73 individuals59 and in 10% of a series of 49 indi-
viduals2, typically presenting as acute coecal volvulus. 
Intestinal malrotation may be recurrent84,85, may present 
in infancy, childhood or puberty as a surgical emergency, 
Classic CdLS
NGS-based (or individual)
screening of known
CdLS genes
Mosaicism testing in tissues
other than lymphocytes
D
ia
gn
os
is
 c
on
fi
rm
ed
D
iagnosis confi
rm
ed
NGS-based screening
of known CdLS genes
Gene-specific testing
dependent on phenotype
Non-classic CdLS
Positive
Positive
Positive
Positive
Negative
Negative
Negative
NegativeDeletion and duplication
testing of NIPBL
Clinical CdLS diagnosis not
confirmed molecularly
Fig. 5 | Molecular diagnostic pathways for Cornelia de Lange syndrome. In individuals with the classic Cornelia de 
Lange syndrome (CdLS) phenotype, the first- line molecular diagnostic approach should be next- generation sequencing 
(NGS)-based screening — either gene panel, whole- exome sequencing (WES) or whole- genome sequencing (WGS) — 
including currently known CdLS genes (NIPBL, SMC1A, SMC3, RAD21, BRD4, HDAC8 and ANKRD11). If NGS is not 
available, molecular testing should begin with targeted sequencing of NIPBL. In individuals with the non- classic CdLS 
phenotype, the phenotype itself may allow experienced clinicians to determine which candidate gene should be 
sequenced first; if this cannot be determined, WES or WGS can be performed. In the case of negative results, NIPBL and 
subsequently the other CdLS genes should be tested for mosaicism using tissues other than blood, for example, 
fibroblasts, buccal swabs or bladder epithelial cells from urine. Deletion and duplication testing of NIPBL can be carried 
out using multiplex ligation- dependent probe amplification (MLPA) or chromosome microarray if first- line testing is not 
WES or WGS, through which deletions and duplications can be readily detected. If WES or WGS are used for first- line 
testing, the data can be investigated further for variants in other genes.
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and may be difficult to diagnose owing to a lack of aware-
ness by physicians, atypical symptoms and difficulties in 
effective communication with affected individuals (R29, 
R30). Coecal volvulus is associated with significant mor-
tality73, which has led to the recommendation of imaging 
to prospectively check gastrointestinal mobility85. Rarely, 
sigmoid volvulus occurs86.
Constipation and rumination occur in 10–15% of 
adults with CdLS2,73 (in individuals with a NIPBL var-
iant: 32%2; in those with SMC1A variants: 43%3; and in 
clinically diagnosed individuals with CdLS: 22–46%2,59). 
Individuals with constipation respond to treatment 
regimens similarly to the general population (R31). 
Diarrhoea (18%), gassiness (48%) and lactose intoler-
ance (18%) are also fairly common2. There is no obvious 
increased association with coeliac disease87.
GERD is the most prevalent and severe gastrointes-
tinal problem and can present in infancy as clinically 
significant dystonic Sandifer- like events88,89. GERD may 
become apparent in a highly variable manner, including 
feeding problems, recurrent (chemical) pneumonias, 
failure to thrive, agitation, restlessness or poor sleep. 
It has been suggested that self- injurious behaviour can 
be (partly) explained by GERD3,90 (R32). GERD tends 
to persist or to worsen with time. In a questionnaire 
study, GERD was more common in individuals with 
NIPBL variants (71%) than in those with SMC1A var-
iants (60%)3. In a small series of 38 individuals with 
NIPBL variants, 55% had GERD91, and in a series of 43 
clinically diagnosed individuals, the disease was more 
common in those with classic phenotypes (known to be 
caused predominantly by NIPBL variants)92. In this study 
group, aged 6–32 years, 65% of participants demon-
strated inflammation of the lining of the oesophagus 
(oesophagitis) at endoscopy. In a study of 49 adolescents 
and adults with CdLS, 75% had GERD confirmed by 
gastrointestinal studies, and endoscopy demonstrated 
Barrett oesophagus in 10%, oesophageal metaplasia in 
9%, eosinophilia in 16% and oesophageal narrowing 
(strictures) in 12%2. In another study, Barrett oesopha-
gus was reported in 12% of individuals aged 6–32 years93. 
Mariani and co- workers59 reported clinical symptoms 
consistent with reflux in 71% of a group of individuals 
with partly molecularly confirmed CdLS, 38% of whom 
had endoscopy- confirmed oesophagitis. Several individ-
uals with long- term GERD have developed oesophageal 
adenocarcinoma at a young adult age92,94. A strong cor-
relation between Barrett oesophagus and oesophageal 
cancer is known in the general population95 and proba-
bly also applies to individuals with CdLS. Surveillance in 
those with Barrett oesophagus is widely recommended, 
although no randomized controlled trial is available that 
shows a more favourable course after surveillance; how-
ever, evidence suggests that it does improve outcome95.
No firm data are available on management results for 
GERD in larger series of individuals with CdLS. In clin-
ical practice, a pragmatic trial with a proton pump inhib-
itor (PPI) in a child or adult with CdLS is preferred. Our 
mutual experience indicates that individuals with CdLS 
and GERD respond to PPIs at sufficiently high doses 
(omeprazole 0.7–3.5 mg per kg per day; for maintenance, 
usually half the dose is needed), similar to neurologically 
impaired individuals in general57,96. Modification of 
enteral nutrition and PPIs form the first- line treatment 
(R33). In case of a lack of response, an endoscopy should 
be considered (R34). Fundoplication and other surgical 
interventions are limited to those individuals with CdLS 
who fail to respond favourably to optimal nutritional and 
medical therapies (R33). Long- term follow- up is indi-
cated as GERD is frequently chronic, which is a major 
risk factor for developing Barrett oesophagus95. Reliable 
surveillance can be performed only by repeated endos-
copies, which puts a substantial burden on the individual 
with CdLS and their family, in particular owing to the 
anaesthesia that is needed for this procedure. In addition, 
we acknowledge that such diagnostic procedures differ in 
various countries for medicolegal and practical reasons. 
We suggest that the pros and cons of surveillance for 
Barrett oesophagus be carefully discussed with the fam-
ily and, if possible, the individual with CdLS. Families 
and physicians should decide jointly what would be the 
optimal care for each person (R35); we therefore refrain 
from a general guideline on this aspect.
Senses
Ophthalmology. Facial features are similar in adults and 
in younger individuals. Some individuals with CdLS 
have facial features that make them seem older than their 
chronological age, but reliable studies using 3D facial 
morphology are not available. Eye manifestations, such 
as synophrys (meeting of the medial eyebrows in the 
midline), thick eyebrows and long eyelashes are almost 
universally present in individuals with CdLS, regard-
less of the gene involved, and form one of the facial 
hallmarks of the syndrome. Ptosis — when the upper 
eyelid droops, obscuring part of the pupil — can occur 
unilaterally (37%) or bilaterally (44%), both in those 
with NIPBL variants and those without a molecularly 
confirmed diagnosis26,97,98. Surgery may be indicated, 
particularly when a compensatory chin lift is evident 
(present in 57%), which can interfere with ambulation, 
or when amblyopia (commonly known as lazy eye) or 
refractive error is thought to be secondary to the ptosis97  
(R36). Blepharitis (25%) and related symptoms — epi-
phora, recurrent conjunctivitis, crusting on lashes, 
chalazion, corneal scars and opacities, and erythematous 
lid margins — can be bothersome, particularly for young 
children97,99. Unilateral or bilateral nasolacrimal duct 
obstruction occurs in 24% of individuals with HDAC8 
variants and in 67–80% of individuals with NIPBL var-
iants41. Treatment of blepharitis is the same as in the 
general population: lid hygiene using baby shampoo or 
proprietary scrubs (R37). Surgical probing and irrigation 
for nasolacrimal duct obstruction should be considered 
only when symptoms are not improved with presump-
tive treatment for blepharitis97. Severe nasolacrimal duct 
obstruction may require nasolacrimal intubation and 
surgical correction (dacryocystorhinostomy)97,98.
Visual impairments occur in 44–53% of individuals 
with NIPBL, SMC1A and HDAC8 variants3,41 and those 
without detectable disease- causing variants98. Spherical 
equivalent of >5.0  D (where D stands for dioptre) is seen 
in 38% of patients, and >10.0 D is seen in 9%97. Hyperopia 
(far- sightedness) is less common (15%), both in those 
Chalazion
Small swelling of the eyelid due 
to a blocked meibomian gland.
658 | oCToBeR 2018 | volume 19 www.nature.com/nrg
C o n S e n S u S  S tat e m e n t
with NIPBL variants and in those who had no mole-
cular testing98. Astigmatism occurs both in molecularly 
confirmed and clinically diagnosed individuals.
As in all individuals with intellectual disabilities, reg-
ular assessment of vision is indicated (R38). Correction 
of refraction should be performed as early as possible 
to prevent amblyopia, although children often refuse 
glasses, and occlusion therapy may be difficult owing 
to an aversion to face touching. Contact lenses may 
be impractical for the same reason and because self- 
injurious behaviour may include hitting, pressing or 
poking of eyes. Surgical refractive procedures might 
improve visual function100.
Optic nerve abnormalities have been reported98. 
A peripapillary pigment ring can be found in up to 83% 
of individuals with CdLS97 as a benign finding without 
clinical consequences. Retinal detachment can occur 
owing to high myopia or self- induced trauma.
Nystagmus (rapid, involuntary eye movements), 
which is typically non- progressive, is found in 14–17% 
of patients97,98. Strabismus is found in 16–26% of individ-
uals with CdLS, with esotropia occurring at a higher fre-
quency than exotropia (61% versus 39%), and is slightly 
more prevalent in individuals with NIPBL variants 
(34.6%) than in individuals without molecular confir-
mation (21.4%)97,98. No specific studies are available on 
the management of strabismus in CdLS; strategies for the 
general population should be followed.
Ears, nose and throat. Individuals with CdLS typically 
have low- set, hairy and malformed ears, and one- third 
have small and stenotic ear canals101. Inspection of the 
eardrum using the common small paediatric speculum 
is frequently difficult, thus cerumen removal or mid-
dle ear evaluation may require sedation for a complete 
assessment.
Middle and inner ear abnormalities in individuals 
with CdLS include malformed ossicles, especially the 
malleus and incus, small mastoids, cochlear abnormali-
ties, malformed vestibules and soft- tissue opacification 
of the tympanomastoid cavity102,103. Findings on tempo-
ral bone computed tomography, especially soft tissue in 
the middle ear, correlate well with audiometric data103, 
and imaging studies are useful to assess the cause of 
hearing loss.
Hearing loss is very common (85–90%) in individu-
als with CdLS101,104,105. It is typically bilateral, present in 
infancy, ranges from mild to severe (40–50%)101 and is 
sensorineural in 25% and conductive in 75%104 (R39). 
In adults, sensorineural hearing loss is reported in 45% 
of individuals with CdLS105.
Conductive hearing loss is often secondary to persis-
tent otitis media with effusion (80–85%), and canal ste-
nosis is present in 30% of individuals with CdLS101,104,106. 
Chronic or serous ear infection (otitis media) and 
chronic sinusitis are common (39%) in adulthood107 
(R40). Initial evaluation of children with CdLS should 
include standard audiometric testing, plus otoacoustic 
emissions testing, auditory brainstem evoked response 
audiometry, or both108, to assess for auditory neuro-
pathies106. Early identification of hearing loss is critical 
to maximize communication skills101. Hearing has been 
reported to improve with time in 50% of adults with 
CdLS, including those with severe hearing loss106. These 
findings indicate longitudinal evaluations of hearing.
Treatment options for hearing loss vary according to 
type and severity of the loss: in chronic or recurrent otitis 
media with effusion, myringotomy and pneumatic ear 
tube insertion are first- line treatments, and if soft tissue 
fills the middle ear and mastoid, mastoidectomy may be 
considered102 (R41). If pneumatic ear tube insertion is 
not effective, a standard hearing aid or a bone- anchored 
hearing aid are safe alternatives, but hearing aids can be 
poorly tolerated109. Cochlear implantation has resulted in 
variable levels of functional gain110,111. Surgical options, 
such as correction of an ossicular malformation, may be 
another option.
In individuals with CdLS, the nose is characterized 
by a low nasal bridge, short and concave nasal ridge and 
easily visible nares. One- third of individuals with CdLS 
experiences recurrent sinus infections, hypothesized to 
be caused by abnormal anatomy and disturbed humoral 
immunity55. Nasal polyps were reported2. Treatment of 
sinus infections should follow guidelines for the general 
population112,113. If an immune deficiency is present, 
more aggressive treatment, including immunoglob-
ulins and prophylactic antibiotic treatment, may be 
indicated62.
Intubation can be difficult in individuals with CdLS, 
owing to a small mouth, small chin, short neck, stiffness 
of the temporomandibular joints and cleft palate52,114. 
Therefore, consultation with an anaesthesiologist before 
surgery is advisable (R42). Complications of anaesthesia 
in adults have been reported53.
Orthopaedics
Children and adults with CdLS receive rehabilitation 
services across their lifespan. Adaptive equipment, 
such as orthotics, tripods, and wheelchairs, can mark-
edly enhance motor functions and mobility, increasing 
quality of life. Moreover, safety equipment (for example, 
helmets, door alarms and seat belt harnesses) limits 
the risk of injuries and should be considered for every 
individual with CdLS.
Musculoskeletal problems are common, irrespective 
of the gene involved. In individuals with NIPBL vari-
ants, major upper limb anomalies are the most frequent 
(25%), whereas in those with variants in other genes, 
such malformations are infrequent (SMC3, HDAC8 and 
RAD21) or absent (SMC1A)3,115. Individuals with trun-
cating NIPBL variants have been reported to particularly 
have major limb defects11,25,26,115.
Major limb anomalies are almost exclusively found in 
the upper limbs, more frequently in male individuals11, 
and are asymmetric in 65% (in 75% of these individ-
uals, the right side is the more affected side)115,116. 
Malformations include an absent forearm, abnormal 
fusion of the radius and ulna (radioulnar synostosis), 
absent radius or ulna, and oligodactyly. Polydactyly 
occurs only rarely. Small hands are present in almost all 
individuals with CdLS; radial head underdevelopment 
and radial dislocation are present in 79% of individuals117; 
other minor anomalies (proximally placed thumbs or 
abnormal curvature (clinodactyly) of the fifth fingers) 
Strabismus
Strabismus (or squint or 
‘crossed eyes’) is non-parallel 
orientation of the visual axes of 
the eyes causing a disturbed 
vision, which can be inwards 
(esotropia) or outwards 
(exotropia).
  volume 19 | oCToBeR 2018 | 659NATuRe RevIeWS | GeneTICS
C o n S e n S u S  S tat e m e n t
are present in 65–85%3,115–118. Several studies in clini-
cally diagnosed individuals with CdLS have suggested 
an association between major limb malformations and 
organ malformations, including diaphragmatic hernia 
and more marked intellectual disability, which likely can 
be explained by the more frequent presence of NIPBL 
variants in those with major limb malformations3,25,115,118.
In individuals with major anomalies, physical ther-
apy or surgical procedures are usually not indicated 
as function is often remarkably good (R43). The use 
of full prosthetic devices has been attempted, but our 
joint experience indicates it is only rarely successful as 
the prostheses are not often accepted. The use of spe-
cific devices, for example, to allow independent eating, 
should be considered, as acceptance of such devices 
can be good (R44, R45). Minor limb anomalies do not 
require therapeutic interventions.
Major malformations of the lower extremities (absent 
tibia or fibula and split foot) are extremely uncom-
mon46,119. Minor leg length differences occur in 46% of 
individuals, and Legg–Calvé–Perthes disease, a hip dis-
order that presents alongside disrupted blood flow to the 
femur, is seen in 4%118. Congenital hip dislocations are 
uncommon, and hip dislocations occur in 10% of indi-
viduals with CdLS later in life, especially in wheelchair- 
bound or bed- ridden individuals, as do tight hamstrings 
and Achilles tendons and contractures59,115. Management 
is as in the general population, taking the prognosis 
with respect to development and mobility into account. 
Preventive measures (physical therapy or orthoses) are 
paramount, and Botox injections and surgery may be 
indicated as well120. Minor lower limb anomalies (small 
feet, cutaneous syndactyly between the second and third 
toes, short fourth metatarsals or inward deviation of 
the big toes (hallux valgus)) are frequently present3,10,59. 
Specifically, deviation of the halluces may increase with 
age and cause walking difficulties59. In adults, 75% of indi-
viduals with CdLS report bunions, albeit without major 
complications; thus, surgical repair is not indicated118.
Scoliosis, especially thoracic scoliosis, develops in 
one- third of patients, often by 10 years of age118, and 
is more common in adults with decreased mobility59 
(R46). Experience of scoliosis surgery is limited, but our 
mutual experience indicates that standard management 
is effective, taking prognosis with respect to develop-
ment and mobility into account. Spine malformations 
are extremely rare and typically asymptomatic121, with 
kyphosis present in one- quarter of these individuals118. 
Flexion contractures have been reported in 18–25% of 
individuals with CdLS, particularly in the knees, which 
can interfere with ambulation, but also in the elbow 
and/or hip, as have tight Achilles tendons118,122.
Neurology
Seizures are common in CdLS (individuals with SMC1A 
variants: 45%; with NIPBL variants: 15%; without molec-
ular confirmation: 20–26%)2,3,123. Truncating SMC1A 
variants with marked seizures have been described in 
women with a Rett- syndrome-like disorder3,31 who do 
not fulfil the diagnostic criteria for CdLS3. In a series 
of 14 clinically diagnosed patients124 and an overview 
of individuals with mostly clinically diagnosed CdLS123, 
partial epilepsy was the most common type; age of onset 
was typically before 2 years of age, and 35 of 39 indi-
viduals for whom full data were available reacted well 
to standard therapy. Specifically, sodium valproate was 
found to be effective124 (R47). Anoxic epileptic seizures 
have been reported rarely125.
Isolated neurological signs, such as dystonia126, and 
catatonia127 are rare. Autonomic nervous system dys-
function, evaluated in a questionnaire study in 65 indi-
viduals with CdLS aged ≥8 years, was mildly disturbed 
in 81% of individuals and markedly disturbed in 26%2. 
Sensory deficits and temperature insensibility have 
been recognized by several of the present authors, but 
robust proof is lacking that this occurs more frequently 
in CdLS. The neuropathy may be linked to self- injurious 
behaviour3.
Structural brain abnormalities can occur, especially 
in individuals with NIPBL variants. NIPBL is known 
to regulate cortical neuron migration in mice128 and, 
indeed, cortical malformations have been described in 
individuals with CdLS caused by NIPBL variants129, as 
have small callosal bodies, white matter abnormalities, 
cerebellar anomalies and brainstem abnormalities. The 
limited number of available neuropathological reports 
confirms these brain anomalies130. In a small study of 15 
clinically diagnosed individuals, no correlation between 
behaviour and magnetic resonance imaging (MRI) 
abnormalities could be detected131. MRI findings usu-
ally do not contribute to regular clinical care and should 
be limited to individuals with CdLS with neurological 
manifestations (R48). The presence of microcephaly in 
an individual with molecularly confirmed CdLS is in 
itself no indication for neuroimaging. Spinal cord abnor-
malities are rare and limited to (typically asymptomatic) 
tethered cord129. A single patient with a thoracic menin-
gocele, a protrusion of the spinal cord through a bone 
defect in the vertebral column, has been reported132.
Sleep- related problems have been reported repeat-
edly, both in individuals with NIPBL and SMC1A var-
iants and in clinically diagnosed individuals, with a 
widely variable frequency (12–72%) and ranging from 
nightly apnoea and insomnia to daytime drowsiness 
and frequent daytime napping90,133–136 (R49). Difficulties 
in falling asleep and staying asleep occur in 55–65% of 
individuals as early as infancy. Consecutive days with-
out sleep were reported in 30% of 74 individuals with 
clinically diagnosed CdLS135. Snoring has been reported 
in 17% of 46 individuals with CdLS in one study136 and in 
63% of 22 individuals with CdLS in another study134 and 
may lead to daytime sleepiness. Behavioural interven-
tions and melatonin may be helpful in treating sleep dis-
orders in those with CdLS (unpublished observations, 
L.M.K and A.Se.). Few adults have been reported to have 
sleep problems135, suggesting spontaneous improvements 
over time.
Cognition and behaviour
Cognition
Individuals with CdLS show intellectual disability that 
ranges from profound to mild; a small proportion per-
forms within the normal range, whereas the majority has 
severe to moderate intellectual disability (Supplementary 
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Tables 1,2). Individuals with SMC1A variants generally 
function at a higher level than those with NIPBL vari-
ants3. The type or site of NIPBL variants seems not to be 
associated with the level of intellectual disability11,26,137, 
although one study reported that missense and in- frame 
deletions were associated with less severe intellectual 
disability138.
Individuals with CdLS may have specific deficits in 
executive function beyond what is expected given the 
level of intellectual disability, especially in mental flex-
ibility and visual short- term memory139. Assessment of 
the cognitive strengths and weaknesses of an individ-
ual and structuring their environment accordingly is 
beneficial. Comparative inhibition, another executive 
function, may be a relative strength140. Profiles of exec-
utive functioning may be associated with particular 
aspects of the CdLS behavioural phenotype, such as 
frequent repetitive behaviour or social anxiety139,140. 
Management strategies should include environmen-
tal enrichment strategies to stimulate cognitive and 
learning abilities.
Sensory processing
Difficulties in sensory processing141 can lead to hypo-
sensitivity and hypersensitivity, confusion and fixa-
tion by sensory stimuli and inconsistent sensation of 
stimuli142,143. Gastrointestinal and other somatic prob-
lems in individuals with CdLS may cause anxiety, 
mood disorders and challenging behaviour, including 
self- injurious behaviour3,109,144. No correlations with 
particular gene variants have been reported145, but our 
mutual clinical experiences suggest that all individuals 
with CdLS have sensory processing difficulties. Sensory 
processing difficulties are present across all levels of 
intellectual disability146; if an autism spectrum disorder 
(ASD) is also present, the behaviour can include low 
sensory thresholds141 and defensive responses towards 
sensory stimuli147. All interventions should address the 
sensory needs in order to enhance development and 
participation in daily living146 (R50).
Adaptive behaviour profile
Individuals with CdLS demonstrate impaired adaptive 
behaviour across the lifespan, which is more marked 
in individuals with variants in NIPBL compared with 
other causes148,149. In CdLS, adaptive behaviour deficits 
are more marked than those with several other genetic 
conditions150, albeit comparable to Angelman syndrome 
and Rubinstein–Taybi syndrome151–153.
Adaptive behaviour skills in CdLS can decrease with 
age10,154. Changes over time can vary by specific skills, 
such as increased mastery with age of specific self- help 
skills (for example, washing and feeding) and decreased 
mastery of other skills (for example, ability to call for 
help or to move independently)109. Lower skill lev-
els observed in older individuals with CdLS in cross- 
sectional studies may be confounded by cohort effects 
or recruitment biases, and true decreases in skills as 
individuals age remain uncertain. Indeed, mixed results 
have been reported109,155, which underlines the need for 
additional longitudinal research on adaptive behaviour 
skills (R51–R53).
Self- injurious and aggressive behaviours
Self- injurious behaviour, that is, any self- directed behav-
iour that causes tissue damage, without intent of suicide 
or sexual arousal, such as self- hitting, head banging 
and self- biting, is frequent in individuals with CdLS156. 
Behaviours identical to self- injurious behaviour but not 
causing tissue damage may develop into self- injurious 
behaviour157. Risk markers for self- injurious behaviour 
include more severely compromised cognitive abilities, 
communication skills and adaptive behaviours, the pres-
ence of genetic variants in NIPBL, and increased levels 
of impulsivity, repetitive behaviours and characteristics 
commonly associated with diagnosis of ASD156. Clinically 
significant self- injurious behaviour occurs in 56% of 
individuals with CdLS, and hand- directed self- injurious 
behaviour is most common158,159. Physical injury in 
self- injurious behaviour can be scored on the basis 
of the amount of tissue damage and functional loss156. 
Restraints may be helpful to avert permanent tissue loss 
and have been used as first- line management107.
Self- injurious behaviour can be a sign of or response 
to pain. Careful medical evaluation is required, as self- 
injurious behaviour is associated with common medi-
cal conditions (GERD, otitis media, constipation, dental 
disease or hip problems). Best practices for the treat-
ment of self- injurious behaviour require an integrated 
approach of medical evaluation, behavioural assess-
ments and consideration of the environment. Treatment 
recommendations are then matched to the function of 
self- injurious behaviour (R54, R55).
There is limited evidence that self- injurious behav-
iour reacts to risperidone160, but this antipsychotic 
agent should only be used with careful monitoring of 
metabolic syndrome, weight gain and cognitive adverse 
effects. No data exist on the use of mood stabilizers in 
the management of individuals with CdLS.
Repetitive behaviour
Repetitive behaviour, that is, behaviour linked by inflexi-
bility, purposelessness, ritualization and (invariant) repe-
tition, is characteristic of certain stages of typical infant 
development but may reappear with age in some disor-
ders, including CdLS, and be aggravated by anxieties, 
sensory issues or social demands161–163. The frequency 
of repetitive behaviours is associated with more marked 
intellectual disability and with ASD161,163. In individuals 
with CdLS, repetitive behaviours can assume discrete 
manifestations, such as stereotyped motor movements, 
insistence on sameness and ritual behaviours, with lining 
up and tidying up being characteristic162.
In individuals with NIPBL variants, no correlation of 
repetitive behaviour with the site or nature of the variant 
was detected10. Studies employing longitudinal designs 
yielded contradictory results for changes over time161,163. 
Interventions should be sensitive to underlying issues, 
for example, anxiety, sensory problems or social 
demands, and consider environmental factors, such as 
predictability in daily structure. Psychopharmacology 
has centred on modulation of the serotonin pathway 
with selective serotonin re- uptake inhibitors (SSRIs) and 
the dopamine pathway with second- generation antipsy-
chotic agents (SGAs). SSRIs are a standard of treatment 
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for obsessive- compulsive disorder, but the effects of 
SSRIs in ASD are not convincing164,165. A cautious 
approach is indicated for the use of SSRIs in patients 
with CdLS because of possible behavioural activation 
and worsening agitation. SGAs may be useful for the 
management of rigidity and need for sameness, which 
can result in disruptive behaviours160.
Social functioning including ASDs
Descriptions of common mental health issues in individ-
uals with CdLS include ASD, (social) anxiety and mood 
disorders109,137,152,154,165–169, which do not seem to be asso-
ciated with the site or nature of the gene variant invol
ved10,137,148,149,169. Measuring psychopathology in CdLS is 
difficult because most affected individuals are unable to 
reliably report their own discomfort, behaviour or feelings. 
Symptoms commonly need to be inferred from proxy 
reports or observed behavioural presentations, such as 
eye- gaze avoidance, pushing away and screaming80,170,171. 
Maladaptive behaviours were positively correlated with 
parental stress levels137 and social context109.
The prevalence of ASD symptomatology in CdLS is 
43%159. In individuals with NIPBL variants, ASD was 
associated with decreased adaptive behaviour skills10. 
ASD should be considered when social, communication 
and behavioural impairments are beyond what would be 
expected for the cognitive level of an individual.
The heightened prevalence of ASD symptomatology 
is not solely accounted for by associated degree of intel-
lectual disability150,172,173. Comparisons of individuals with 
CdLS to those with ASD indicate broad similarities but 
subtle differences in specific areas of communication and 
social interaction173, especially social anxiety, extreme 
shyness and selective mutism2,65,109,150,152. The differences 
become more prominent with age and with increased 
social demand, and an individualized approach that is 
sensitive to these CdLS- specific aspects should make 
interventions more successful65,166,174. Rating scales and 
direct observational measures can provide a fine- grained 
evaluation of social functioning. Social motivation, social 
communication and enjoyment are substantially lower in 
those with CdLS in contrast to matched groups of indi-
viduals with other syndromes151 and are comparable to 
these traits in individuals with ASD175. This finding high-
lights the importance of detailed observations when eval-
uating ASD and social behaviour and of understanding 
the level and characteristics of communicative, adaptive 
and language abilities of those with CdLS. ASD- specific 
interventions may be helpful when used in conjunction 
with approaches that consider the broader social profile 
of the syndrome (R56–R58).
Anxiety
Anxiety is common as a primary condition in individu-
als with CdLS, usually as generalized anxiety, separation 
anxiety168, selective mutism148 or as an exacerbating fac-
tor for repetitive behaviours, mood- related symptoms or 
disruptive, aggressive and self- injurious behaviours109. 
Anxiety may be difficult to assess, especially in individ-
uals with challenging behaviours137. Social interactions 
can provoke anxiety and lead to observable behavioural 
responses, such as fidgeting, avoiding eye gaze and 
active avoidance of social interaction152,175. Individuals 
with CdLS have a heightened preference for sameness 
and have difficulties responding to changes in routine, 
which can make transitional periods more challenging 
and provoke anxiety148,162,174 (R59-R62).
Communication and language
Communication abilities vary widely in individuals with 
CdLS but, typically, major difficulties are present, par-
ticularly in expressive language skills170,176,177, although 
well- developed speech and language can occur138,174.
Phonation, speech and mastication can be compro-
mised in individuals with CdLS secondary to general 
abnormal muscle tone. Speech may also be impaired 
owing to hearing loss or morphological abnormalities 
of the palate, mandible and temporomandibular joint. 
Vision is also important for communication. Cognitive 
impairment can further complicate communication and 
understanding of communication176,178.
Individuals with CdLS tend to vocalize with a low- 
pitched cry and speak with a monotone voice140,179 
regardless of cognitive level. Studies relating speech 
characteristics to genetic findings are lacking. There is 
a shortage of studies on the relationship between intel-
lectual functioning, behaviour and communication abil-
ities169. Selective mutism occurs as part of ASD or as an 
expression of anxiety148,152. In a small study of 17 individu-
als with CdLS, expressive language was found to be more 
compromised than receptive language, and receptive lan-
guage compromised more than cognition, with specific 
deficits in morphosyntactic competences138. Expressive 
language is limited regardless of cognitive level.
In individuals with profound intellectual disabilities, 
communication is mostly determined by and depend-
ent on sensitive responsiveness of the environment, and 
communicative signals are often subtle and easily over-
looked178. Difficulties in social interaction and anxiety 
can worsen language skills138 and decrease intentional 
communicative behaviour compared with that of other 
individuals with a similar cognitive level but without dif-
ficulties in social interactions170. Challenging behaviours 
often co- occur with communication difficulties3 (R63).
Effective verbal and non- verbal communication skills 
can facilitate quality of life enormously, and speech ther-
apy is highly recommended to optimize communication 
skills and should be implemented within the first 18 
months of age (R64). Assessment of the level of com-
munication of an individual and possible impediments 
are required for effective intervention of communica-
tion, as well as knowledge of suitable support tools180. 
Early augmentative and alternative communication 
interventions, tackling communication deficits from 
the beginning with specific attention to wide augmented 
communication input, are highly recommended138,181,182. 
Commonly used tools are gestures, icons, pictures and 
written language. Suitability differs by person, and a 
tailored approach is indicated.
Typically, parents are experts in understanding 
the communicative signals of their child. The experi-
ence they have acquired over the years is indispensa-
ble in cooperation with behavioural specialists and 
speech therapists. Detecting and identifying small 
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communicative signals, awareness of one’s own reaction 
and understanding their meaning facilitates adjustment 
of communication and responses. Responsive milieu 
teaching and video observations can be very helpful in 
detecting and identifying such communication signals, 
their meanings and appropriate responses, especially in 
individuals with marked cognitive impairments183,184.
Age- related changes in cognition and behaviour
Studies have reported age- related changes in behav-
iour, emotion and cognition2,137,139,148,172. In a study of 42 
individuals with NIPBL variants, a (fairly weak) positive 
correlation was observed between chronological age and 
behavioural difficulties137, and statistically significant 
correlations were found between chronological age and 
measures of interest and pleasure, and insistence on same-
ness148, indicating older individuals exhibit more difficul-
ties. Studies of clinically diagnosed individuals with CdLS 
have reported changes in verbal working memory, ASD 
symptomatology, anxiety, low mood, self- injurious behav-
iour and impulsivity2,90,109,139,154,166,172,174, indicating increas-
ing difficulties in frequency and severity with age. Similar 
changes were not found for aggression, hyper activity or 
sleep difficulties. The associations with age have been 
documented through correlation analyses. Studies using 
age- band analyses have identified that adolescence and 
early adulthood are periods of marked change109,167,172. 
Management strategies should include evaluation of social 
environment, support during transitional periods using 
a person- centred approach and gradual introduction of 
changes. Coordination of the support for the individual 
with CdLS by a named caregiver is helpful (R65).
Care planning
Medical care
A diagnosis of CdLS necessitates lifelong medical, multi-
disciplinary and social care, regardless of the molecu-
lar aetiology. Access to clinical evaluation, counselling 
and follow- up by a multidisciplinary team is likely 
to improve health care and increase quality of life. 
Recognized barriers to accessing care include health or 
behavioural complications, geographical isolation and 
financial considerations185–187. Individuals with CdLS are 
now likely to live into adulthood and old age and thus 
risk developing common chronic diseases in addition to 
CdLS- related morbidities. They are more likely to expe-
rience delayed treatment, to be hospitalized and to have 
more complications and longer admissions than individ-
uals without CdLS owing to lack of knowledge regarding 
CdLS by caregivers, difficulties in obtaining a reliable 
earlier history and, possibly, stigmatization. The use 
of syndrome- specific, individualized treatment plans, 
including regular health checks, planning of admissions 
and discharges in advance, and the use of procedure- 
specific information booklets using simple language and 
photos are recommended188,189 (R66, R67).
Transition
Transition of medical care from a paediatric to an adult 
care team comes with substantial challenges190 and 
requires parental involvement. Typically, transition 
coincides with changes in daytime environment, leaving 
home and legally mandated social changes. Care changes 
from family- focused to affected- individual-focused. 
Transitions that are initiated too late can result in a gap 
in communication and coordination between paediatric 
and adult services. Parents have suggested that care may 
be improved by establishing joint child and adult care 
clinics109,191,192 (R68).
Decision- making
The involvement of individuals with CdLS and their care 
providers in health- care decisions is essential. A marked 
degree of intellectual disability and executive functioning 
in individuals with CdLS can decrease decision- making 
capacities; if so, care providers and health- care profes-
sionals have to decide what is best and document values, 
preferences and quality of life193. Knowledge about CdLS 
is essential to manage expectations, and health- care pro-
viders and social services need to be aware of the needs 
and problems that can be expected. Family support 
groups and social media have proved to be extremely 
helpful in this respect194,195. Guardianship rules vary 
among countries, and it is essential for guardianship to 
be determined and assigned before the age of majority.
Conclusions
The present recommendations provide a framework for 
improving diagnosis and management of CdLS. CdLS 
is a complex disorder, in which many body systems 
are affected, and it is important that a lead clinician is 
identified for each patient to ensure coordination of the 
numerous aspects of care in both childhood and adult-
hood. The proposed clinical and molecular diagnostic 
pathways are intended to be universally practical, both 
in countries with access to modern techniques and in 
those where this is not yet possible, and they are meant 
to be cost- effective, avoiding unnecessary diagnostic or 
management procedures. Still, in some health- care sys-
tems and medicolegal environments, the guidelines may 
need to be adapted. It is important that implementation 
of the consensus recommendations is accompanied by 
prospective audits in order to expand the evidence base 
and allow for future ameliorations of the consensus.
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